Fluid and imaging biomarkers for Alzheimer's disease: Where we stand and where to head to

作者：Henriques Adriane Dallanora; Benedet Andrea Lessa; Camargos Einstein Francisco; Rosa Neto Pedro; Nobrega Otavio Toledo^*

来源：Experimental Gerontology, 2018, 107: 169-177.

DOI：10.1016/j.exger.2018.01.002

• Alzheimer
• Mild cognitive impairment
• Biomarker
• Cerebrospinal fluid
• Diagnosis
• Neuroimaging

There is increasing evidence that a number of potentially informative biomarkers for Alzheimer disease (AD) can improve the accuracy of diagnosing this form of dementia, especially when used as a panel of diagnostic assays and interpreted in the context of neuroimaging and clinical data. Moreover, by combining the power of CSF biomarkers with neuroimaging techniques to visualize A beta deposits (or neurodegenerative lesions), it might be possible to better identify individuals at greatest risk for developing MCI and converting to AD. The objective of this article was to review recent progress in selected imaging and chemical biomarkers for prediction, early diagnosis and progression of AD. We present our view point of a scenario that places CSF and imaging markers on the verge of general utility based on accuracy levels that already match (or even surpass) current clinical precision.

• 出版日期2018-7-1
• 单位McGill